Asset Management One Co. Ltd. Increases Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Asset Management One Co. Ltd. increased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 69,310 shares of the biopharmaceutical company’s stock after purchasing an additional 853 shares during the period. Asset Management One Co. Ltd. owned 0.05% of Alnylam Pharmaceuticals worth $22,601,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Bessemer Group Inc. grew its position in shares of Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 69 shares during the period. Crossmark Global Holdings Inc. purchased a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at $275,000. Strs Ohio purchased a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at $7,781,000. GAMMA Investing LLC grew its position in shares of Alnylam Pharmaceuticals by 14.3% in the first quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company’s stock valued at $166,000 after purchasing an additional 77 shares during the period. Finally, Brighton Jones LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $243,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 0.1%

Shares of ALNY opened at $463.43 on Friday. The stock’s 50-day moving average is $459.27 and its two-hundred day moving average is $360.97. The stock has a market cap of $60.75 billion, a PE ratio of -187.62 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.86. The company had revenue of $773.69 million for the quarter, compared to analysts’ expectations of $633.54 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The firm’s quarterly revenue was up 17.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.13) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, Director Michael W. Bonney sold 11,250 shares of the business’s stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $450.00, for a total transaction of $5,062,500.00. Following the transaction, the director owned 16,804 shares in the company, valued at $7,561,800. The trade was a 40.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Jeffrey V. Poulton sold 3,821 shares of the business’s stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $1,727,283.05. Following the completion of the transaction, the executive vice president owned 54,052 shares in the company, valued at approximately $24,434,206.60. This trade represents a 6.60% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 98,144 shares of company stock valued at $44,160,261 over the last 90 days. Corporate insiders own 1.50% of the company’s stock.

Analyst Ratings Changes

ALNY has been the topic of a number of research analyst reports. Canaccord Genuity Group lifted their target price on Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a “buy” rating in a report on Friday, August 1st. Citigroup lifted their target price on Alnylam Pharmaceuticals from $527.00 to $583.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. BMO Capital Markets lifted their target price on Alnylam Pharmaceuticals from $450.00 to $470.00 and gave the company an “outperform” rating in a report on Friday, September 5th. UBS Group lifted their target price on Alnylam Pharmaceuticals from $403.00 to $550.00 and gave the company a “buy” rating in a report on Friday, August 1st. Finally, The Goldman Sachs Group lifted their target price on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the company a “buy” rating in a report on Tuesday, September 16th. Twenty-three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $466.92.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.